Skip to the reference entry
Notice: This is NOT an official government website. We are not affiliated with any government agency.
GOV Health ReportIndependent Health Resource Portal

Reference entry

Cagrilintide

Read the scope, examine the source, and keep your own question alongside the evidence.

Status labels apply within the product, route, and use described below. Read the limitations alongside that scope.

Scoped product status
Investigational
Evidence label
Randomized evidence

Status as of

Reference fields

Sources for these fields

Product and use
Investigational; no FDA-approved product.
Route context
Studied as a subcutaneous injection.
Mechanism
A long-acting amylin analogue.
Evidence
A randomized weight-management trial was funded by Novo Nordisk.
Limitations
Combination results cannot be assigned to a single ingredient.
Safety
The trial reported gastrointestinal and injection-site reactions.

Sources

These references support the fields as a group. Follow a source to check the original wording and its scope.

  1. LauPubMed · Checked
  2. FDA GLP-1FDA · Checked

Continue reading

Reading topics: Metabolism. These organize the library and do not describe recommended uses.

Educational reference information. No clinician review is claimed. This entry does not provide personal medical advice.